Structure-Based Virtual Screening, Molecular Docking, and Molecular Dynamics Simulation of VEGF inhibitors for the clinical treatment of Ovarian Cancer
Sourav Mukherjee,Mohnad Abdalla,Manasi Yadav,Maddala Madhavi,Anushka Bhrdwaj,Ravina Khandelwal,Leena Prajapati,Aravind Panicker,Aashish Chaudhary,Ashraf Albrakati,T. Hussain,Anuraj Nayarisseri,Sanjeev Kumar Singh +12 more
TL;DR: In this article , a potential vascular endothelial growth factor (VEGF) inhibitor was identified for ovarian cancer using various in-silico approaches, which is playing a crucial role in stimulating the immunosuppressive microenvironment in tumor cells.
read more
Abstract: Vascular endothelial growth factor (VEGF) and its receptor play an important role both in physiologic and pathologic angiogenesis, which is identified in ovarian cancer progression and metastasis development. The aim of the present investigation is to identify a potential vascular endothelial growth factor inhibitor which is playing a crucial role in stimulating the immunosuppressive microenvironment in tumor cells of the ovary and to examine the effectiveness of the identified inhibitor for the treatment of ovarian cancer using various in silico approaches. Twelve established VEGF inhibitors were collected from various literatures. The compound AEE788 displays great affinity towards the target protein as a result of docking study. AEE788 was further used for structure-based virtual screening in order to obtain a more structurally similar compound with high affinity. Among the 80 virtual screened compounds, CID 88265020 explicates much better affinity than the established compound AEE788. Based on molecular dynamics simulation, pharmacophore and comparative toxicity analysis of both the best established compound and the best virtual screened compound displayed a trivial variation in associated properties. The virtual screened compound CID 88265020 has a high affinity with the lowest re-rank score and holds a huge potential to inhibit the VGFR and can be implemented for prospective future investigations in ovarian cancer.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
A comprehensive review on recent approaches for cancer drug discovery associated with artificial intelligence
Sanjeevi Pandiyan,Li E. Wang +1 more
TL;DR: In this paper , the authors explored molecular docking and their interactions to recognize metabolic activities that support drug design and highlighted corresponding strategies in applying machine and deep learning methods to various types of cancer with their pros and cons.
20
Structure-Based Virtual Screening, Molecular Docking, Molecular Dynamics Simulation of EGFR for the Clinical Treatment of Glioblastoma
Anushka Bhrdwaj,Mohnad Abdalla,Aditi Pande,Maddala Madhavi,Ishita Chopra,Love Kumar Soni,Natchimuthu Vijayakumar,Umesh Panwar,Mohd. Aqueel Khan,Leena Prajapati,Pranoti Belapurkar,Sarah Albogami,T. Hussain,Chandrabose Selvaraj,Anuraj Nayarisseri,Sanjeev Kumar Singh +15 more
TL;DR: In this paper , a newly screened chemical (PubChem CID: 59,671,768) with a higher affinity than the previously known molecule was used for virtual screening of glioblastoma.
Structure-Based Virtual Screening, Molecular Docking, Molecular Dynamics Simulation and Pharmacokinetic modelling of Cyclooxygenase-2 (COX-2) inhibitor for the clinical treatment of Colorectal Cancer
Manasi Yadav,Mohnad Abdalla,Maddala Madhavi,Ishita Chopra,Anushka Bhrdwaj,Love Kumar Soni,Uzma Shaheen,Leena Prajapati,Megha Sharma,Mayank Singh Sikarwar,Sarah Albogami,T. Hussain,Anuraj Nayarisseri,Sanjeev Kumar Singh +13 more
TL;DR: The conclusion suggests that the virtual screened compound (PubChem ID: 10151468) could be a potential therapeutic for the treatment of colorectal cancer.
13
Potential inhibitors of VEGFR1, VEGFR2, and VEGFR3 developed through Deep Learning for the treatment of Cervical Cancer
Anuraj Nayarisseri,Mohnad Abdalla,Isha Joshi,Manasi Yadav,Anushka Bhrdwaj,Ishita Chopra,Arshiya Khan,Anil Kumar Saxena,Khushboo Sharma,Aravind Panicker,Umesh Panwar,Francisco Jaime Bezerra Mendonça,Sanjeev Kumar Singh +12 more
TL;DR: In-silico drug discovery for VEGFR-1, VEGFR-2, and VEGFR-3 inhibitors targeting cervical cancer. The study identified potent inhibitors and explored their binding affinities and molecular dynamics.
SPOCK2 Promotes the Malignant Behavior of Ovarian Cancer via Regulation of the Wnt/β-Catenin Signaling Pathway
TL;DR: Overexpressed SPOCK2 was identified in OC, which was correlated with poor prognosis and a shorter survival rate, but could serve as a promising candidate for OC targeted therapy.
3
References
SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules
TL;DR: The new SwissADME web tool is presented that gives free access to a pool of fast yet robust predictive models for physicochemical properties, pharmacokinetics, drug-likeness and medicinal chemistry friendliness, among which in-house proficient methods such as the BOILED-Egg, iLOGP and Bioavailability Radar are presented.
admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties.
TL;DR: An ADMET structure-activity relationship database that collects, curates, and manages available ADMET-associated properties data from the published literature, and provides a user-friendly interface to query a specific chemical profile, using either CAS registry number, common name, or structure similarity.
1.8K
A BOILED-Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules
Antoine Daina,Vincent Zoete +1 more
TL;DR: The Brain Or IntestinaL EstimateD permeation method (BOILED‐Egg) is proposed as an accurate predictive model that works by computing the lipophilicity and polarity of small molecules.
1.8K
•Journal Article
ZD6474 Inhibits Vascular Endothelial Growth Factor Signaling, Angiogenesis, and Tumor Growth following Oral Administration
Stephen R. Wedge,Donald J. Ogilvie,Michael Dukes,Jane Kendrew,Rosemary Chester,Janet A. Jackson,Sarah J. Boffey,Paula J. Valentine,Jon Curwen,Helen Musgrove,George A Graham,Gareth D Hughes,Andrew Peter Thomas,Stokes Elaine Sophie Elizabeth,Brenda Curry,Graham Richmond,Peter F. Wadsworth,Alison L. Bigley,Laurent Francois Andre Hennequin +18 more
TL;DR: ZD6474 is a potent, p.o. active, low molecular weight inhibitor of kinase insert domain-containing receptor that demonstrates selectivity against a range of other tyrosine and serine-threonine kinases and translates into potent inhibition of vascular endothelial growth factor-A (VEGF)-stimulated endothelial cell proliferation in vitro.
888
Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity
Nilofer S. Azad,Edwin M. Posadas,Virginia Kwitkowski,Seth M. Steinberg,Lokesh Jain,Christina M. Annunziata,Lori M. Minasian,Gisele Sarosy,Herbert L. Kotz,Ahalya Premkumar,Liang Cao,Deborah McNally,Catherine Chow,Helen X. Chen,John J. Wright,William D. Figg,Elise C. Kohn +16 more
TL;DR: Combination therapy with sorafenib and bevacizumab has promising clinical activity, especially in patients with ovarian cancer, but the rapidity and frequency of sorAFenib dose reductions indicates that sorafanib at 200 mg twice daily with bevacsumab 5 mg/kg every 2 weeks may not be tolerable long term, and alternate sorafinib dosing schedules should be explored.
341